Brief: Proqr Announces Additional Sepofarsen Illuminate Trial Analyses

ProQR Therapeutics NV

13/04/2022 12:20

April 13 (Reuters) - ProQR Therapeutics NV  PRQR.O :
    * PROQR ANNOUNCES ADDITIONAL SEPOFARSEN ILLUMINATE TRIAL
ANALYSES
AND PROVIDES UPDATE ON COMPANY STRATEGY
    * PROQR THERAPEUTICS NV- WILL IMPLEMENT RESTRUCTURING
INITIATIVES
INCLUDING A 30% WORKFORCE REDUCTION, EXTENDING CASH RUNWAY INTO
2025
    * PROQR THERAPEUTICS NV - IN Q3, COMPANY PLANS TO MEET WITH
EMA
AND FDA TO DISCUSS DATA FROM ILLUMINATE TRIAL
    * PROQR THERAPEUTICS - CURRENTLY PLANS TO CONTINUE
ILLUMINATE,
WHICH IS A 2 YEAR STUDY, BRIGHTEN PEDIATRIC STUDY, INSIGHT,
UNTIL FURTHER REGULATORY GUIDANCE
    * PROQR THERAPEUTICS NV - NO FURTHER INVESTMENTS ARE PLANNED
AT
THIS TIME FOR NEW TRIALS OF SEPOFARSEN OR COMMERCIAL
PREPARATIONS
    * PROQR THERAPEUTICS NV - SUSPEND DEVELOPMENT OF QR-1123 FOR
AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA AND QR-504A FOR FUCHS
ENDOTHELIAL CORNEAL DYSTROPHY
    * PROQR THERAPEUTICS NV - SUSPEND ALL OTHER IRD-RELATED
RESEARCH
ACTIVITIES
    * PROQR THERAPEUTICS NV- NO TECHNICAL ERRORS IN POST-HOC
ANALYSES
OF ILLUMINATE TRIAL CONDUCT, DATA HANDLING, OR DRUG PRODUCT USED
    * PROQR THERAPEUTICS - FOCUS ULTEVURSEN (QR-421A) PROGRAM ON
SINGLE PHASE 2/3 SIRIUS TRIAL WITH POTENTIAL ADDITION OF
INTERIM/FUTILITY ANALYSIS IN 2023
    * PROQR THERAPEUTICS NV- OVERALL SAFETY PROFILE OF
SEPOFARSEN IN
POST-HOC ANALYSES WAS CONSISTENT WITH EARLIER TRIALS
    * PROQR THERAPEUTICS - WILL ACCELERATE DEVELOPMENT OF
AXIOMER RNA
EDITING PLATFORM AND PIPELINE ACTIVITIES AND EXPAND INTO AREAS
BEYOND EYE

Source text for Eikon:  ID:nGNXwlTnP 
Further company coverage:  PRQR.O 

 ((reuters.briefs@thomsonreuters.com;))